The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis

被引:31
|
作者
Schweitzer, Nora [1 ]
Weber, Tim [1 ]
Kirstein, Martha M. [1 ]
Fischer, Mareike [1 ,2 ]
Kratzel, Anna-Maria [1 ]
Reineke-Plaass, Tanja [3 ]
Lehner, Frank [4 ]
Manns, Michael P. [1 ]
Vogel, Arndt [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Klinikum Hildesheim, Dept Cardiol Angiol & Intens Care, Senator Braun Allee 33, D-31135 Hildesheim, Germany
[3] Hannover Med Sch, Dept Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Cholangiocarcinoma; CCA; Intrahepatic; ICC; Survival; Adjuvant chemotherapy; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; MORTALITY-RATES; UNITED-STATES; TRENDS; SURVIVAL; BILIARY; EXPERIENCE; INCREASE; CANCER;
D O I
10.1007/s00432-017-2392-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
引用
收藏
页码:1347 / 1355
页数:9
相关论文
共 50 条
  • [41] Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
    Zhu, Andrew X.
    Knox, Jennifer J.
    ONCOLOGIST, 2012, 17 (12): : 1504 - 1507
  • [42] Evaluation of Postoperative Adjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma Patients undergoing R1 and R2 Resections
    Bhudhisawasdi, Vajarabhongsa
    Talabnin, Chutima
    Pugkhem, Ake
    Khuntikeo, Narong
    Seow, O-Tur
    Chur-in, Siri
    Pairojkul, Chawalit
    Wongkham, Sopit
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 : 169 - 174
  • [43] Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: Chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy
    Lin, Yen-Kuang
    Hsieh, Mao-Chih
    Wang, Wei-Wei
    Lin, Yi-Chun
    Chang, Wei-Wen
    Chang, Chia-Lun
    Cheng, Yun-Feng
    Wu, Szu-Yuan
    RADIOTHERAPY AND ONCOLOGY, 2018, 128 (03) : 575 - 583
  • [44] Outcomes Following Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Matched Analysis
    Holzner, M. L.
    Parvin-Nejad, F.
    Fei, K.
    Florman, S.
    Schwartz, M. E.
    Tabrizian, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 488 - 488
  • [45] Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy
    d'Abrigeon, Constance
    Mcnamara, Mairead G.
    Le Sourd, Samuel
    Lamarca, Angela
    Lievre, Astrid
    Bourien, Heloise
    Peinoit, Alexandre
    Uguen, Thomas
    Hubner, Richard A.
    Valle, Juan W.
    Edeline, Julien
    BRITISH JOURNAL OF CANCER, 2023, 129 (11) : 1766 - 1772
  • [46] Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy
    D'abrigeon, Constance
    McNamara, Mairead Geraldine
    Le Sourd, Samuel
    Lamarca, Angela
    Lievre, Astrid
    Hubner, Richard A.
    Valle, Juan W.
    Edeline, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Survival Impact of Neoadjuvant Chemoradiation versus Chemotherapy on Patients with Intrahepatic Cholangiocarcinoma
    Patel, Hardik Y.
    Kushmakov, Robert
    Baker, Matthew
    Lee, Bryan
    Butler, Kevin
    Basem, Azab
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S246 - S246
  • [48] Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy
    Constance d’Abrigeon
    Mairéad G. McNamara
    Samuel Le Sourd
    Angela Lamarca
    Astrid Lièvre
    Héloïse Bourien
    Alexandre Peinoit
    Thomas Uguen
    Richard A. Hubner
    Juan W. Valle
    Julien Edeline
    British Journal of Cancer, 2023, 129 : 1766 - 1772
  • [49] Efficacy of Adjuvant Chemotherapy and Prognostic Factors for Patients With Extrahepatic Cholangiocarcinoma
    Lee, Hee Seung
    Oh, Tak Geun
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    Bang, Seungmin
    GASTROENTEROLOGY, 2014, 146 (05) : S879 - S879
  • [50] The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma
    Morino, Koshiro
    Seo, Satoru
    Yoh, Tomoaki
    Nishino, Hiroto
    Yamanaka, Kenya
    Fukumitsu, Ken
    Ishii, Takamichi
    Taura, Kojiro
    Okajima, Hideaki
    Kaido, Toshimi
    Uemoto, Shinji
    ANTICANCER RESEARCH, 2019, 39 (04) : 2155 - 2161